Skip to main content
Clinical Trials/NL-OMON29736
NL-OMON29736Not yet recruitingNot Applicable

B-UVB phototherapy versus Excimerlaser after minigrafting in vitiligo patients - NB-UVB versus Excimerlaser after minigrafting

Academisch Medisch Centrum0 sites24 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
24

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • i. Consecutive patients, diagnosed with stable vitiligo vulgaris* with symmetrical vitiligo patches
  • *Vitiligo vulgaris: a few to many widespread depigmented macules over the entire body, with often a symmetrically distribution pattern.
  • Stable means: no expansion of existing lesions or appearance of new lesions during the previous 6 months, absence of Koebner*s phenomenon and a positive minigrafting test
  • ii. Patients, eligible for minigrafting and NB-UVB/excimer therapy
  • iii. Adult patients: * 18 years
  • iv. Patients who have given written informed consent

Exclusion Criteria

  • i. With a history of hypertrophic scarring and/or keloid
  • ii History of allergic/phototoxic reaction (Lidocaine, Tegaderm, Suture strips, sunlight)
  • iii With a negative minigrafting test
  • iv With a personal or a family history of skin cancer (non-melanoma skin cancer: first degree family members, melanoma: any family member)
  • v. With a personal history of photosensitivity and/or phototoxicity disorders
  • vi. With skin type I (according to Fitzpatrick classification I-VI)
  • vii. Who are pregnant
  • viii. Who are taking medications known to cause photosensitivity and/or phototoxicity and chronic or very frequent use of any medication that can influence the UVB response (eg. tetracycline, retinoids, sulfonamids, psoralens, NSAID*s)
  • ix. With other skin diseases that would impair evaluation of repigmentation, such as psoriasis and eczema.
  • x. Who are not able to have 2 times weekly NB-UVB/Excimer therapy.
  • xi. With local immunosuppressive treatment or 6 weeks prior to enrolment. For these patients a washout period of 6 weekswill be required.

Investigators

Similar Trials